On Monday, Nurix Therapeutics Inc (NASDAQ: NRIX) was 18.68% up from the session before settling in for the closing price of $18.09. A 52-week range for NRIX has been $8.18 – $22.95.
A company in the Healthcare sector has dropped its sales by -38.86% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -8.56%. With a float of $99.81 million, this company’s outstanding shares have now reached $101.37 million.
Nurix Therapeutics Inc (NRIX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nurix Therapeutics Inc stocks. The insider ownership of Nurix Therapeutics Inc is 1.53%, while institutional ownership is 82.45%. The most recent insider transaction that took place on Nov 24 ’25, was worth 641,697. In this transaction Chief Legal Officer of this company sold 37,600 shares at a rate of $17.07, taking the stock ownership to the 50,897 shares. Before that another transaction happened on Nov 24 ’25, when Company’s Officer proposed sale 37,600 for $16.76, making the entire transaction worth $630,176.
Nurix Therapeutics Inc (NRIX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 11/30/2024, it has been observed that the corporation posted -0.75 earnings per share (EPS) during the time that was less than consensus figure (set at -0.67) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.26% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
You can see what Nurix Therapeutics Inc (NRIX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.93 in the next quarter and is forecasted to reach -3.42 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.44 million. That was better than the volume of 1.07 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.80%.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 92.80%, which indicates a significant increase from 89.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.20 in the past 14 days, which was higher than the 0.71 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.67, while its 200-day Moving Average is $11.57. However, in the short run, Nurix Therapeutics Inc’s stock first resistance to watch stands at $22.58. Second resistance stands at $23.68. The third major resistance level sits at $24.87. If the price goes on to break the first support level at $20.29, it is likely to go to the next support level at $19.10. Assuming the price breaks the second support level, the third support level stands at $18.00.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
There are 76,883K outstanding shares of the company, which has a market capitalization of 2.18 billion. As of now, sales total 54,550 K while income totals -193,570 K. Its latest quarter income was 7,890 K while its last quarter net income were -86,420 K.
